What The Lundquist Institute Does

The Lundquist Institute for Biomedical Innovation, formerly the Los Angeles Biomedical Research Institute, is a non-profit, academic-affiliated research organization based on the campus of Harbor-UCLA Medical Center. Founded in 1952, it operates at a significant scale (1,001-5,000 employees) to bridge the gap between laboratory discovery and patient application. Its core mission involves conducting groundbreaking clinical and translational research across a wide spectrum, including infectious diseases, cardiovascular medicine, cancer, and diabetes. The institute manages extensive clinical trials, maintains large biorepositories of human tissue and blood samples, and fosters innovation through its incubator spaces for biotech startups. This unique position—embedded in a major medical center yet operating as an independent research engine—generates a rich and continuous flow of structured clinical data and complex biological datasets.

Why AI Matters at This Scale

For a research institute of Lundquist's size, AI is not a futuristic concept but a present-day multiplier of research velocity and impact. The volume and variety of data generated—from electronic health records (EHRs) and genomic sequences to medical imaging and proteomic assays—far exceed the capacity of traditional analytical methods. At this employee scale, the institute has the critical mass to support a dedicated data science or AI core team, yet it remains agile enough to pilot and integrate new technologies faster than a sprawling university system. AI provides the tools to uncover hidden patterns in this data, generating novel hypotheses, predicting experimental outcomes, and personalizing therapeutic approaches. Failure to adopt these tools risks falling behind peer institutions in the race for publications, patents, and lucrative grant funding from agencies like the NIH, which increasingly favor data-science-driven proposals.

Concrete AI Opportunities with ROI Framing

1. Accelerated Drug Repurposing & Discovery: By applying graph neural networks and deep learning to its molecular and clinical trial databases, Lundquist can rapidly identify existing drugs that could be effective against new diseases. The ROI is measured in years shaved off the traditional drug development timeline and millions saved in R&D costs for each successful repurposing candidate, directly translating to more licenses and partnerships with pharmaceutical companies.

2. Intelligent Clinical Trial Management: Machine learning models can predict patient dropout risk and optimize site performance in real-time during trials. This directly addresses the single largest cost in clinical research—patient recruitment and retention. A 10-20% improvement in trial efficiency and completion rates can save hundreds of thousands of dollars per study and get therapies to market faster.

3. Automated Scientific Insight Generation: Deploying Large Language Model (LLM) agents to continuously read and synthesize the global corpus of scientific literature can keep researchers ahead of trends. The ROI is the recovered time for principal investigators—estimated at 15-20 hours per month—that can be redirected to experimental design and high-value analysis, boosting overall institutional productivity.

Deployment Risks Specific to This Size Band

Organizations in the 1,000-5,000 employee range face unique AI deployment challenges. They possess enough data to be valuable but often lack the enterprise-grade, unified data infrastructure of larger corporations, leading to siloed data lakes that hinder model training. Funding AI initiatives competes directly with core research budgets, requiring clear, project-specific ROI justifications rather than blanket corporate investment. There is also a significant talent risk: attracting and retaining top machine learning scientists is difficult when competing with the salaries and prestige of big tech and large pharma. Finally, at this scale, there is often no dedicated Chief Data or AI Officer, leading to fragmented ownership where IT, research administration, and individual labs may have misaligned priorities, slowing cohesive strategy execution.